SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas upcoming quarterly results are drawing attention, with traders focused on AI spending guidance and whether the Muse rollout can support future growth. The community is split between expecting strong results and an AI-driven boost, and worrying that rising capex, weak near-term returns and the reported New Mexico privacy penalty could weigh on the stock.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong Q3 results and plans to rapidly expand AI-compute capacity are driving bullish interest, amplified by analyst upgrades and discussion of a potential Tesla merger. Traders remain divided, with some emphasizing growth and AI demand while others cite heavy capital spending, valuation concerns and a large share unlock as risks to the rally.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives expanded Bitcoin treasury, supported by proceeds from its SATS preferred-stock offering, is driving bullish attention as traders point to continued BTC accumulation and momentum in the shares. Others warn that the preferred financing adds dividend obligations and claims ahead of common shareholders, tempering the bullish view.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas upcoming quarterly results are driving heavy attention, with traders split on whether the pre-earnings rally can hold amid concerns about margins and the companys outlook. Speculation over a possible SpaceX mergerwhose independent committees are exploring a combination but have agreed to no termsadds to the bullish excitement and deal-structure concerns.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its quarterly earnings report, with traders focused on guidance and what it may signal about AI-related and memory-chip equipment demand. The stocks pre-earnings slide has prompted debate between buyers expecting strong results and traders wary of high expectations, volatility, and further downside.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is centered on traders positioning around the full Phase 3 INTerpath-001 melanoma vaccine data with Merck at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the cancer-vaccine opportunity, while bears warn that expectations and valuation are stretched and debate whether the event could trigger a sell-the-news pullback.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

Shares are drawing attention on speculation that SpaceX could invest in or partner with Skydance, after John Malone floated a potential multibillion-dollar deal. Traders are reacting bullishly to the prospect of new financing and distribution opportunities, though the deal remains unconfirmed and bears continue to point to Skydances heavy debt and warrant-related volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 decision on deramiocel for Duchenne muscular dystrophy, with the current application focused on upper-limb function. Traders are split: supporters point to the Phase 3 endpoint and extension data, while skeptics cite the prior rejection, advisory committee vote, and disputed statistical analyses; the stocks weakness has also prompted unverified short-selling and manipulation claims.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy selling pressure amid repeated lockup expirations and reported insider sales, with traders also citing a lower analyst price target and concerns about OpenAI customer concentration and competition. Bearish calls for further declines contrast with bulls arguing the selloff is overdone and the companys AI-chip technology has long-term potential.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

TD Cowens downgrade to Hold, citing softer October sales and a challenging sales outlook, is weighing on Chipotle shares ahead of earnings. Traders are debating whether the selloff reflects deeper traffic and food-quality concerns or creates a buying opportunity, with some also pointing to recent price increases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Schrdinger to Announce Third Quarter 2026 Financial Results on November 4

Schrdinger, Inc. (Nasdaq: SDGR) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers...

Schrdinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

Schrdinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center...

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?

SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Closing Power Hour: Biotech, AI, Energy and Crypto Stories Take Center Stage

The final stretch of trading is bringing a fresh batch of catalysts across biotech, energy, AI and digital assets, with the following names delivering developments capable of reshaping their narratives. Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), Turbo Energy (NASDAQ:TURB), CID HoldCo (NASDAQ:DAIC), Paradium.AI (NYSE:PAAI), StablecoinX (NASDAQ:USDE), FuelCell Energy (NASDAQ:FCEL), and Schrödinger (NASDAQ:SDGR).

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrdinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the companys common stock to three newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive...

SDGR Crosses Above Average Analyst Target

In recent trading, shares of Schrodinger Inc (Symbol: SDGR) have crossed above the average analyst 12-month target price of $21.43, changing hands for $23.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valu...

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033

AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033PR NewswireAUSTIN, Texas, Sept. 14, 2026 AUSTIN, Texas, Sept. 14, 2026 /PRNewswire/ -- USA News Group News Commentary- Artificial intelligence is moving from the edges...

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Equity

Bearish Sentiment

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35.&nbsp;The firm said recent stumbles in Schrodinger’s homegrown drug programs, along with persistent headwinds across biotech and pharma, have dimmed its outlook.<a href="https://stocktwits.com/symbol/SDGR">Shares of Schrodinger</a> fell 2% to $19.45 on Thursday, marking its lowest close in four months, before edging up 0.2% to $19.5 in after-hours trading.The downgrade by the brokerage firm came just after Schrodinger disclosed that it will&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/schrodinger-discontinues-clinical-program-after-two-patient-deaths/chsR0RyRdOb">discontinue the development of SGR-2921</a>, an early-stage CDC7 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.Chief Medical Officer Margaret Dugan said patient safety was the company’s top priority, noting that the drug’s potential as a combination therapy would be challenging to pursue under the circumstances. “While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” she said.Citi said its earlier bullish stance had hinged on three early-stage Phase 1 assets that could validate Schrodinger’s drug discovery platform and attract biopharma partners.&nbsp;The brokerage firm noted that updates so far have “fallen short,” fueling concerns about the future of the company’s internal drug portfolio.SGR-2921 was&nbsp;designed to block CDC7 kinase, a protein overexpressed in many cancers and involved in DNA replication and cell cycle progression.&nbsp;Preclinical data had suggested the drug could work in combination with standard-of-care agents, but Schrodinger said the safety risks outweighed the potential benefits.On Stocktwits, retail sentiment for Schrodinger was ‘bearish’ amid ‘extremely high’ message volume.One user questioned the timing of Schrodinger’s disclosure, noting that the company reported Q2 earnings just eight days ago, and&nbsp;wondered if both patient deaths occurred since then or if the information had been withheld.&nbsp;<stembedurl>https://stocktwits.com/scott52/message/625133866</stembedurl>Another user speculated that there was “more to the news” than disclosed, pointing to the stock’s quick price recovery as a sign that “something fishy” might be going on.<stembedurl>https://stocktwits.com/Buckanator/message/625153259</stembedurl>Schrodinger’s stock has risen 0.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Schrodinger logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$23.93
Prev Close	$23.40
Open	$23.39
Dividend Yield	0.00%
50-Day Moving Average	$23.72
Beta	1.64
Avg. Volume	2.38M
PE Ratio	-31.76

52-Week High	$33.78
52-Week Low	$10.95
Market Capitalization	$1.75B
EPS (Annual)	-$1.41
Price to Book	5.32
Revenue Per Employee	$301,022.35

Feed

News

Sentiment

Earnings

Fundamentals

Info

SDGR Fundamentals